Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium
Provided By GlobeNewswire
Last update: Sep 18, 2025
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients
Read more at globenewswire.comNASDAQ:ZVRA (11/14/2025, 9:54:07 AM)
9.28
+0.05 (+0.54%)
Find more stocks in the Stock Screener
